Get started
Author

Madhu Sanga

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations
2023 · Elias Jabbour, Emma Searle, et al. · Blood · 52
Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with KMT2A and NPM1 Alterations
2024 · Emma Searle, Christian Recher, et al. · Blood · 42
An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia
2016 · Madhu Sanga, Joyce James, et al. · Xenobiotica · 33
Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with KMT2Ar or NPM1 Alterations
2024 · Christian Recher, Jenny O'Nions, et al. · Blood · 27
PDF
Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers
2016 · Madhu Sanga, John Banach, et al. · Xenobiotica · 19
Absorption, Metabolism, and Excretion of [14C]‐Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open‐Label, Mass‐Balance Study
2012 · Monette M. Cotreau, Christine L. Hale, et al. · Clinical Pharmacology in Drug Development · 15
Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation☆
2005 · M SANGA, I YOUNIS, et al. · Toxicology and Applied Pharmacology · 10
Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment
2023 · Thomas N. Kakuda, Atef Halabi, et al. · The Journal of Clinical Pharmacology · 6
Absorption, Metabolism, and Excretion of Quizartinib (AC220), a FLT3 Tyrosine Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, in Healthy Male Volunteers
2012 · Jianke Li, Gayle Bresnahan, et al. · Blood · 5
[Effects of demeclocycline on psychiatric polydipsia in schizophrenic patients].
1999 · M Sanga, M Kurotani, et al. · PubMed · 3
Lorpucitinib (JNJ-64251330) in patients with familial adenomatous polyposis (FAP): Results from a phase 1b study.
2023 · Robert Hüneburg, Marcia Cruz-Correa, et al. · Journal of Clinical Oncology · 2
A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants
2023 · Xuewen Ma, Gary Borzillo, et al. · Clinical Pharmacology & Therapeutics · 1
Randomized, double-blind, two-way crossover bioequivalence and adhesion study, in healthy women, of a transdermal contraceptive patch with a newly sourced adhesive component at the end of shelf life vs. the EVRA patch at the beginning of shelf life
2021 · Madhu Sanga, Subusola Vaughan, et al. · International Journal of Clinical Pharmacology and Therapeutics · 1
POSTER: AML-388 Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations
2025 · Elias Jabbour, Christian Recher, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-388: Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations
2025 · Elias Jabbour, Christian Recher, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-412 Bleximenib Dose Optimization and Determination of the Recommended Phase 2 Dose (RP2D) From a Phase 1 Study in Patients With Relapsed/Refractory Acute Leukemia (AL) With KMT2A and NPM1 Alterations
2025 · Hagop M. Kantarjian, Emma Searle, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-412: Bleximenib Dose Optimization and Determination of the Recommended Phase 2 Dose (RP2D) From a Phase 1 Study in Patients With Relapsed/Refractory Acute Leukemia (AL) With KMT2A and NPM1 Alterations
2025 · Hagop M. Kantarjian, Emma Searle, et al. · Clinical Lymphoma Myeloma & Leukemia
Methamphetamine toxicity: Thermal degradation, CYP450-mediated metabolic activation and cytotoxic epoxide formation.
2004 · Madhu Sanga
Works count: 18
Citation count: 216
H-index: 7
I10-index: 7
Year
Topic
Type